Axel Le Cesne

27.1k total citations · 8 hit papers
265 papers, 14.6k citations indexed

About

Axel Le Cesne is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Gastroenterology. According to data from OpenAlex, Axel Le Cesne has authored 265 papers receiving a total of 14.6k indexed citations (citations by other indexed papers that have themselves been cited), including 212 papers in Pulmonary and Respiratory Medicine, 120 papers in Oncology and 73 papers in Gastroenterology. Recurrent topics in Axel Le Cesne's work include Sarcoma Diagnosis and Treatment (164 papers), Gastrointestinal Tumor Research and Treatment (73 papers) and Vascular Tumors and Angiosarcomas (66 papers). Axel Le Cesne is often cited by papers focused on Sarcoma Diagnosis and Treatment (164 papers), Gastrointestinal Tumor Research and Treatment (73 papers) and Vascular Tumors and Angiosarcomas (66 papers). Axel Le Cesne collaborates with scholars based in France, Netherlands and United States. Axel Le Cesne's co-authors include Jean‐Yves Blay, Sylvie Bonvalot, Jaap Verweij, M. van Glabbeke, Ian Judson, Antoîne Italiano, Paolo G. Casali, Isabelle Ray‐Coquard, Patrick Schöffski and Pancras C.W. Hogendoorn and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Communications.

In The Last Decade

Axel Le Cesne

260 papers receiving 14.3k citations

Hit Papers

Metronomic cyclophosphamide regimen selectively depletes ... 2006 2026 2012 2019 2006 2006 2009 2016 2009 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
    2006 968 citations Axel Le Cesne et al. profile →
  2. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
    2006 654 citations Maria Dêbiec‐Rychter, Raf Sciot et al. European Journal of Cancer profile →
  3. Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas
    2009 624 citations Isabelle Ray‐Coquard, M. van Glabbeke et al. profile →
  4. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
    2016 539 citations Patrick Schöffski, Antoîne Italiano et al. profile →
  5. Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
    2009 535 citations Stefan Sleijfer, Isabelle Ray‐Coquard et al. Journal of Clinical Oncology profile →
  6. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
    2012 455 citations Isabelle Ray‐Coquard, Jean‐Yves Blay et al. profile →
  7. Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
    2009 397 citations George D. Demetri, Jean‐Yves Blay et al. Journal of Clinical Oncology profile →
  8. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial
    2012 383 citations Axel Le Cesne, Sylvie Bonvalot et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Axel Le Cesne France 62 9.7k 7.1k 2.7k 2.6k 2.5k 265 14.6k
Shreyaskumar Patel United States 63 10.9k 1.1× 6.0k 0.8× 3.2k 1.1× 2.7k 1.1× 2.5k 1.0× 260 14.7k
Angelo Paolo Dei Tos Italy 67 10.9k 1.1× 6.1k 0.9× 4.5k 1.6× 2.4k 0.9× 2.5k 1.0× 438 17.0k
Peter Hohenberger Germany 57 9.0k 0.9× 5.1k 0.7× 1.7k 0.6× 2.0k 0.8× 4.1k 1.6× 369 13.8k
Axel Le Cesne France 56 7.9k 0.8× 4.3k 0.6× 2.1k 0.8× 1.9k 0.7× 2.6k 1.0× 270 10.6k
Antoîne Italiano France 67 9.2k 0.9× 9.0k 1.3× 2.3k 0.8× 2.1k 0.8× 684 0.3× 618 17.5k
Jean‐Michel Coindre France 73 12.4k 1.3× 7.5k 1.1× 4.9k 1.8× 4.0k 1.6× 904 0.4× 296 17.7k
Suzanne George United States 55 6.8k 0.7× 3.7k 0.5× 863 0.3× 1.3k 0.5× 4.0k 1.6× 257 11.7k
Alessandro Gronchi Italy 78 15.7k 1.6× 7.3k 1.0× 7.5k 2.7× 4.5k 1.7× 2.4k 1.0× 469 19.4k
Margaret von Mehren United States 55 10.7k 1.1× 4.1k 0.6× 1.0k 0.4× 1.1k 0.4× 9.3k 3.7× 282 16.3k
Christine Chevreau France 54 10.2k 1.1× 6.2k 0.9× 1.2k 0.4× 1.4k 0.6× 538 0.2× 310 15.6k

Countries citing papers authored by Axel Le Cesne

Since Specialization
Citations

This map shows the geographic impact of Axel Le Cesne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Axel Le Cesne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Axel Le Cesne more than expected).

Fields of papers citing papers by Axel Le Cesne

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Axel Le Cesne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Axel Le Cesne. The network helps show where Axel Le Cesne may publish in the future.

Co-authorship network of co-authors of Axel Le Cesne

This figure shows the co-authorship network connecting the top 25 collaborators of Axel Le Cesne. A scholar is included among the top collaborators of Axel Le Cesne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Axel Le Cesne. Axel Le Cesne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Saleh, Khalil, et al.. (2024). Updates on Chimeric Antigen Receptor T-Cells in Large B-Cell Lymphoma. Biomedicines. 12(12). 2810–2810. 1 indexed citations
2.
Penel, Nicolas, Sylvie Bonvalot, Alexandra Meurgey, et al.. (2022). Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type Fibromatosis. Clinical Cancer Research. 28(18). 4105–4111. 13 indexed citations
3.
Grimison, Peter, Christine Chevreau, Silvia Stacchiotti, et al.. (2022). Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours. European Journal of Cancer. 173. 219–228. 17 indexed citations
4.
Nassif, Elise F., Édouard Auclin, Rastilav Bahleda, et al.. (2021). TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials. Cancers. 13(13). 3362–3362. 7 indexed citations
5.
Cesne, Axel Le, Perrine Marec‐Bérard, Jean‐Yves Blay, et al.. (2019). Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. European Journal of Cancer. 119. 151–157. 114 indexed citations
6.
Sanfilippo, Roberta, Robin L. Jones, Jean‐Yves Blay, et al.. (2019). Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas). Clinical Cancer Research. 25(17). 5295–5300. 75 indexed citations
7.
Mir, Olivier, Nathan Touati, Michela Lia, et al.. (2019). Impact of Concomitant Administration of Gastric Acid–Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials. Clinical Cancer Research. 25(5). 1479–1485. 64 indexed citations
8.
Brodowicz, Thomas, Olivier Mir, Jennifer Wallet, et al.. (2018). Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. European Journal of Cancer. 99. 28–36. 15 indexed citations
9.
Salas, Sébastien, Céline Brulard, Philippe Terrier, et al.. (2015). Gene Expression Profiling of Desmoid Tumors by cDNA Microarrays and Correlation with Progression-Free Survival. Clinical Cancer Research. 21(18). 4194–4200. 31 indexed citations
10.
Woźniak, Agnieszka, Piotr Rutkowski, Patrick Schöffski, et al.. (2014). Tumor Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumors of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST. Clinical Cancer Research. 20(23). 6105–6116. 121 indexed citations
11.
Bonvalot, Sylvie, Nils Ternès, Marco Fiore, et al.. (2013). Spontaneous Regression of Primary Abdominal Wall Desmoid Tumors: More Common than Previously Thought. Annals of Surgical Oncology. 20(13). 4096–4102. 162 indexed citations
12.
Demetri, George D., Patrick Schöffski, Manisha H. Shah, et al.. (2012). Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure. Clinical Cancer Research. 18(11). 3170–3179. 102 indexed citations
13.
Ray‐Coquard, Isabelle, Antoîne Italiano, Emmanuelle Bompas, et al.. (2012). Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO). The Oncologist. 17(2). 260–266. 148 indexed citations
14.
Duffaud, Florence, Caroline Even, Isabelle Ray‐Coquard, et al.. (2012). Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients. SHILAP Revista de lepidopterología. 2(1). 11–11. 2 indexed citations
15.
Salas, Sébastien, Armelle Dufresne, Binh Bui, et al.. (2011). Prognostic Factors Influencing Progression-Free Survival Determined From a Series of Sporadic Desmoid Tumors: A Wait-and-See Policy According to Tumor Presentation. Journal of Clinical Oncology. 29(26). 3553–3558. 268 indexed citations
16.
Sleijfer, Stefan, Isabelle Ray‐Coquard, Zsuzsa Pápai, et al.. (2009). Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043). Journal of Clinical Oncology. 27(19). 3126–3132. 535 indexed citations breakdown →
17.
Ray‐Coquard, Isabelle, Axel Le Cesne, Jeremy Whelan, et al.. (2008). A Phase II Study of Gefitinib for Patients with Advanced HER-1 Expressing Synovial Sarcoma Refractory to Doxorubicin-Containing Regimens. The Oncologist. 13(4). 467–473. 48 indexed citations
18.
Bonvalot, Sylvie, Hany Eldweny, Vincent Haddad, et al.. (2007). Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. European Journal of Surgical Oncology. 34(4). 462–468. 211 indexed citations
19.
20.
Cesne, Axel Le, Ian Judson, John Radford, et al.. (2000). Phase II study of ET-743 in advanced soft-tissue sarcoma (ASTS) in adult: A STBSG-EORTC trial. Annals of Oncology. 11. 126–126. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shreyaskumar Patel Breakdown of academic impact, for papers by Angelo Paolo Dei Tos Breakdown of academic impact, for papers by Peter Hohenberger Breakdown of academic impact, for papers by Axel Le Cesne Breakdown of academic impact, for papers by Antoîne Italiano Breakdown of academic impact, for papers by Jean‐Michel Coindre Breakdown of academic impact, for papers by Suzanne George Breakdown of academic impact, for papers by Alessandro Gronchi Breakdown of academic impact, for papers by Margaret von Mehren Breakdown of academic impact, for papers by Christine Chevreau
Rankless by CCL
2026